Skip to main navigation
Header Menu
Logo
  • About
    • Overview
    • Management
    • Board of Directors
  • Products
    • SYMJEPI® (epinephrine)
    • ZIMHI™ (naloxone)
  • Pipeline
    • Specialty Pharmaceuticals
    • APC-400 (tempol) – Capsule
  • Patients
  • Investors & Media
    • Overview
    • News Releases
    • Stock Information
    • SEC Filings
    • Events & Presentations
    • Email Alerts
    • Governance
  • Careers
    • Careers
    • Partnerships
  • Contact Us

News Releases

Date Title View
Nov 14, 2022 Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
PDF Version
Nov 07, 2022 Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update
PDF Version
Oct 03, 2022 Adamis Announces Review of Strategic Alternatives
PDF Version
Sep 21, 2022 Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
PDF Version
Sep 12, 2022 Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects
PDF Version
Aug 12, 2022 Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
PDF Version
Aug 10, 2022 Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
PDF Version
Aug 08, 2022 Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
PDF Version
Jul 29, 2022 Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
PDF Version
Jul 29, 2022 Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
PDF Version

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »

Sign Up For Adamis Email Alerts

Choose Your Preferences
Adamis Pharmaceuticals Corporation logo

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease.

02. Footer - Social Links
  • LinkedIn
  • Twitter
Footer - Column 2
COMPANY
  • About Us
  • Overview
  • Management
  • Board of Directors
Products
  • SYMJEPI® (epinephrine)
  • ZIMHI® (naloxone)
Pipeline
  • Specialty Pharmaceuticals
  • APC-400 (tempol) – Capsule
Footer - Column 3 (Hidden on Desktop)
Investors & Media
  • Overview
  • News Releases
  • Stock Information
  • SEC Filings
  • Events & Presentations
  • Email Alerts
  • Corporate Governance
Connect
  • Careers
  • Partnerships
  • Contact Us
Footer - Column 4
Products
  • SYMJEPI® (epinephrine)
  • ZIMHI® (naloxone)
Pipeline
  • Specialty Pharmaceuticals
  • APC-400 (tempol) – Capsule
Footer - Column 5
Investors & Media
  • Overview
  • News Releases
  • Stock Information
  • SEC Filings
  • Events & Presentations
  • Email Alerts
  • Corporate Governance
Footer - Column 6
Connect
  • Careers
  • Partnerships
  • Contact Us

© 2023 Copyright Adamis Pharmaceuticals Corporation

Footer Copyright Links
  • Terms and Conditions
  • Privacy Policy